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Cardiovascular complications are the leading cause of death for patients with type 2 diabetes mellitus, a dis-
ease affecting >20 million people in the United States.1 The 
inflammatory response associated with diabetes mellitus 
and the resultant vascular injury initiate more severe dia-
betic cardiovascular complications, including atherosclerosis 
and ischemic heart disease.2 Defining the mechanisms lead-
ing to inflammatory vascular injury in diabetes mellitus and 
identifying novel therapeutic strategies capable of protecting 
vascular function are therefore in great need.
Adiponectin is an adipocyte-derived cytokine. In con-
trast to the majority of adipokines (eg, tumor necrosis fac-
tor [TNF]-α), which are proinflammatory and significantly 
increased in patients with diabetes mellitus, adiponectin is a 
potent vascular protective molecule that is markedly reduced 
in patients with type 2 diabetes mellitus.3–5 Adiponectin 
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© 2014 American Heart Association, Inc.
Circulation Research is available at http://circres.ahajournals.org DOI: 10.1161/CIRCRESAHA.114.302439
Rationale: Anti-inflammatory and vascular protective actions of adiponectin are well recognized. However, many 
fundamental questions remain unanswered.
Objective: The current study attempted to identify the adiponectin receptor subtype responsible for adiponectin’s 
vascular protective action and investigate the role of ceramidase activation in adiponectin anti-inflammatory 
signaling.
Methods and Results: Adiponectin significantly reduced tumor necrosis factor (TNF)α–induced intercellular 
adhesion molecule-1 expression and attenuated TNFα-induced oxidative/nitrative stress in human umbilical vein 
endothelial cells. These anti-inflammatory actions were virtually abolished by adiponectin receptor 1 (AdipoR1-), 
but not AdipoR2-, knockdown (KD). Treatment with adiponectin significantly increased neutral ceramidase 
(nCDase) activity (3.7-fold; P<0.01). AdipoR1-KD markedly reduced globular adiponectin–induced nCDase 
activation, whereas AdipoR2-KD only slightly reduced. More importantly, small interfering RNA-mediated 
nCDase-KD markedly blocked the effect of adiponectin on TNFα-induced intercellular adhesion molecule-1 
expression. AMP-activated protein kinase-KD failed to block adiponectin-induced nCDase activation and 
modestly inhibited adiponectin anti-inflammatory effect. In contrast, in caveolin-1 KD (Cav1-KD) cells, >87% of 
adiponectin-induced nCDase activation was lost. Whereas adiponectin treatment failed to inhibit TNFα-induced 
intercellular adhesion molecule-1 expression, treatment with sphingosine-1-phosphate or SEW (sphingosine-1-
phosphate receptor agonist) remained effective in Cav1-KD cells. AdipoR1 and Cav1 colocalized and coprecipitated 
in human umbilical vein endothelial cells. Adiponectin treatment did not affect this interaction. There is weak 
basal Cav1/nCDase interaction, which significantly increased after adiponectin treatment. Knockout of AdipoR1 
or Cav1 abolished the inhibitory effect of adiponectin on leukocyte rolling and adhesion in vivo.
Conclusions: These results demonstrate for the first time that adiponectin inhibits TNFα-induced inflammatory 
response via Cav1-mediated ceramidase recruitment and activation in an AdipoR1-dependent fashion.  (Circ Res. 
2014;114:792-805.)
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reduces oxidative/nitrative stress, protects endothelial cells 
from apoptosis, inhibits leukocyte–endothelial interaction, 
and decreases smooth muscle proliferation.6 Two adiponectin 
receptors (AdipoR1 and AdipoR2) have been cloned.7 They 
belong to a new family of membrane receptors (the progestin 
and adiponectin, C1Q and collagen domain-containing recep-
tor superfamily)8–10 predicted to contain 7 transmembrane do-
mains but are topologically distinct from G protein coupled 
receptor. Although both AdipoR1 and AdipoR2 are expressed 
in vascular endothelial cells, their roles in adiponectin-medi-
ated anti-inflammatory and vascular protective actions have 
not been clarified.
Vasodilatory and vascular protective effects of adipo-
nectin have been attributed previously to AMP-activated 
protein kinase (AMPK)–mediated endothelial nitric oxide 
synthase phosphorylation and nitric oxide production.11,12 
However, we recently demonstrated that in the ischemic/
reperfused heart, adiponectin’s antioxidative/antinitrative 
effects are largely AMPK independent.13,14 Moreover, a re-
cent study demonstrates that adiponectin activates neutral 
ceramidase (nCDase) in an adiponectin receptor–dependent 
but AMPK-independent fashion.15 As ceramidase is a key 
enzyme converting ceramide, a proinflammatory molecule, 
to sphingosine-1-phosphate (S1P), an anti-inflammatory and 
cardiovascular protective molecule,16–20 it is possible that adi-
ponectin’s anti- inflammatory and vascular protective effect is 
mediated by ceramidase activation. However, direct evidence 
supporting this attractive notion is currently lacking.
Therefore, the aims of the current study were to (1) iden-
tify the adiponectin receptor subtype responsible for vascular 
protective action; (2) determine the role of ceramidase acti-
vation in adiponectin-mediated anti-inflammatory signaling; 
and (3) investigate whether AdipoR1 functions as a cerami-
dase or mediates ceramidase activation through other signal-
ing molecules.
Methods
Cell Culture and Treatments
Human umbilical vein endothelial cells (HUVECs; passage 2–3) 
were plated on 6-well plates and cultured in endothelial growth me-
dium containing 10% fatal bovine serum, 2 mmol/L glutamine, 100 
U/mL penicillin, and 100 μg/mL streptomycin at 37°C and 5% CO2. 
On 80% confluence, cells were treated with vehicle, globular adipo-
nectin (gAPN; 2 μg/mL)14 or full-length adiponectin (fAPN; 10 μg/
mL). One hour after adiponectin treatment, 10 ng/mL recombinant 
human TNFα protein21 was added. Cells were collected 12 hours after 
TNFα treatment and oxidative/nitrative stress and intercellular adhe-
sion molecule-1 (ICAM-1) expression were determined as described 
in detail below.
Small Interfering RNA Transfection, Plasmid 
Construction, and Transfection
Small interfering RNA (siRNA) duplexes against Cav1,22 AdipoR1,23 
AdipoR2,23 AMPKα1,23 and nCDase24 were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Universal control oligo-
nucleotides (AllStars) from Santa Cruz served as negative control. 
HUVECs (80% confluent) were transfected via siIMPORTER siRNA 
transfection kit (Qiagen Science Inc, Benelux) per manufacturer’s 
protocol (final siRNA concentration: 50 nmol/L).
Ceramidase Enzyme Activity Assay
The nCDase enzyme activity was determined as previously reported, 
with minor modification.25 Briefly, at experiment conclusion, cells 
were collected and washed twice with PBS. Cell pellets were resus-
pended in 100-μL 0.25-mol/L sucrose solution, sonicated, and cen-
trifuged at 15 000g for 3 minutes. The supernatant was collected and 
protein concentration was determined. A 25-μL sample containing 
identical protein amount, 75-μL 25-mmol/L phosphate buffer (pH 
7.4), and 0.5-μL 4-mmol/L Rbm14-12 substrate solution in ethanol 
(final substrate concentration 40 μmol/L; final ethanol concentration 
1%) were loaded into each well of a 96-well plate. The same incuba-
tion mixture without supernatant served as negative control. The plate 
was incubated at 37°C for 1 hour without agitation. The enzymatic 
reaction was stopped by adding 25-μL methanol and 100-μL NaIO4 (2.5 mg/mL) in 200-mmol/L glycine/NaOH buffer (pH 10.6) to each 
well. The plate was placed in a dark room for 1 hour. Fluorescent in-
tensity was quantified via SpectraMax Microplate Reader (Molecular 
Devices, λex 355 nm, λem 446 nm).
Determination of Superoxide and  
Peroxynitrite Content
Superoxide content was quantified by lucigenin enhanced lumines-
cence, and the cellular origin of reactive oxygen species was deter-
mined by dihydroethidium staining (Molecular Probes, Carlsbad, 
CA) as previously described.26 Nitrotyrosine content, the footprint 
of peroxynitrite formation, was quantified by ELISA as previously 
described.26,27
Confocal Immunofluorescence Microscopy
Thirty minutes after vehicle or gAPN treatment, HUVECs were fixed 
with 4% paraformaldehyde/PBS in μ-Slide (ibidi LLC, Verona, WI) 
for 15 minutes followed by PBS washing. Cells were first treated with 
antibodies against AdipoR1, caveolin-1 (Cav1), or nCDase, followed 
by incubation with tetramethyl rhodamine–conjugated antirabbit IgG 
and Cy5-conjugated antigoat IgG. For ceramide and S1P staining, 
cells were fixed with 4% paraformaldehyde/PBA for 2 minutes. Cells 
were then washed with ddH2O (2 minutes) and TBS (pH 7.6; 5 min-
utes). The primary antibodies were prepared with TBS solution con-
taining 5 μmol/L of CaCl2 and cells were incubated with antibody 
for 2 hours at room temperature. After 10-minute washing with TBS 
under agitation, cells were incubated with florescence-labeled sec-
ondary antibody. Slides were visualized by a FV1000 confocal mi-
croscope with ×60 oil-immersion objective lenses (Olympus, Tokyo, 
Japan). Fluorescent images were obtained by a digital camera and 
analyzed with Fluoview software (Olympus).
Immunoblotting and Coimmunoprecipitation
HUVECs were lysed with cold lysis buffer.28,29 After homogenization 
and centrifugation, the supernatant was collected. For immunoblotting, 
proteins were separated on SDS-PAGE gels and transferred to nitrocel-
lulose membranes. Membranes were then incubated with primary an-
tibodies and horseradish peroxidase-conjugated secondary antibody. 
Nonstandard Abbreviations and Acronyms
AdipoR1 adiponectin receptor 1
AdipoR2 adiponectin receptor 2
AMPK AMP-activated protein kinase
Cav1 caveolin-1
fAPN full-length adiponectin
gAPN globular adiponectin
HUVEC human umbilical vein endothelial cells
ICAM-1 intercellular adhesion molecule-1
KD knockdown
KO knockout
nCDase neutral ceramidase
siRNA small interfering RNA
TNF tumor necrosis factor
 at Thomas Jefferson Universi on October 12, 2014http://circres.ahajournals.org/Downloaded from 
794  Circulation Research  February 28, 2014
The blot was developed with a Supersignal Chemiluminescence de-
tection kit (Pierce, Rockford, IL). Bands were visualized by a Kodak 
Image Station 4000R Pro (Rochester, NY). For coimmunoprecipita-
tion, cell lysates were precleared with corresponding nonimmune IgG 
and incubated together with protein A plus-Sepharose for 30 min-
utes at 4°C. Cleaned lysates were then incubated with 2 μg of either 
 anti-Cav1 or anti-nCDase antibodies. Cell lysates were then incubat-
ed with protein A plus-Sepharose overnight at 4°C. Nonimmune rab-
bit IgG served as negative control. Protein A beads were then washed 
extensively with lysis buffer. Proteins were eluted from beads and 
resolved by elusion buffer. Samples with 2×SDS sample buffer were 
heated and separated by electrophoresis. After transfer to polyvinyli-
dene fluoride membranes, proteins were immunoblotted with anti-
AdipoR1 (for Cav1/AdipoR1 interaction) or anti-Cav1 (for Cav1/
ceramidase interaction) as described above.
Intravital Microscopy Analysis of Leukocyte  
Rolling and Adhesion
Leukocyte rolling and adhesion were assayed in mesenteric post-
capillary venules by intravital microscopy as we previously de-
scribed.30 In brief, mice were pretreated with gAPN (first dose: 
1.0 μg/g, IP, 24 hours before TNFα administration; second dose: 
1 μg/g, IP). Thirty minutes after the second dose of adiponectin, 
mice were treated with recombinant TNFα (1.0 μg/kg, IP) for 2 
hours. After exteriorization of a loop of ileum tissue via a mid-
line laparotomy, the ileum was placed in a temperature-controlled 
fluid-filled Plexiglas chamber and transilluminated for bright-field 
observation of the peri-intestinal microcirculation. The ileum and 
mesentery were perfused throughout the experiment with a buffered 
K-H solution (pH 7.4; 37°C). Three to 4 straight, unbranched seg-
ments of postcapillary venules with lengths of >100 μm and diam-
eters between 25 and 40 μm were studied in each mouse using an 
Eclipse FN1 Microscope (Nikon Corp), and the image was recorded 
and analyzed on A WIN XP Imaging Workstation. Leukocyte roll-
ing was defined as the number of leukocytes rolling past a fixed 
point per minute; leukocyte adherence was defined as the number 
of leukocytes firmly adhered to 100-μm length of endothelium for 
≥30 seconds. Rolling and adhesion were measured 4 hours after 
TNFα injection. Venular blood velocity (V) was measured using the 
Microvessel Velocity OD-RT optical Doppler velocimeter (Circusoft 
Instrumentation) with corresponding software. Venular wall shear 
rate (γ) was calculated using the formula: γ=4.9×8(V
mean
/D), where 
D is the venule diameter.
Statistical Analysis
All values in the text and figures are presented as mean±SEM of n 
independent experiments. All data (except Western blot density) were 
subjected to ANOVA followed by Tukey correction for post hoc t test. 
Western blot densities were analyzed by the Kruskal–Wallis test fol-
lowed by Dunn’s post hoc test. Probabilities of ≤0.05 were consid-
ered statistically significant.
Results
Anti-Inflammatory, Antioxidative, and  
Antinitrative Effects of Adiponectin Are  
Mediated Largely by AdipoR1
Treatment of HUVEC with TNFα elicits significant inflam-
matory response31 as evidenced by upregulated ICAM-1 ex-
pression (Figure 1), amplified superoxide generation, and 
increased nitrotyrosine formation (Figure 2). Consistent 
with previous reports, treatment with gAPN significantly 
inhibited TNFα-induced ICAM-1 expression (Figure 1B), 
inhibited superoxide generation (Figure 2A), and decreased 
nitrotyrosine formation (Figure 2C). To identify the recep-
tor subtype(s) responsible for gAPN’s aforementioned anti- 
inflammatory actions, expression of AdipoR1 and AdipoR2 
were genetically inhibited by siRNA (Figure 1A). Consistent 
with previous reports, expression level of AdipoR1 is 
higher than AdipoR2 in HUVEC (relative mRNA abun-
dance [normalized against GAPDH]: AdipoR1=0.67±0.04; 
AdipoR2=0.31±0.03; P<0.01). This expression patter is 
not altered by acute TNFα treatment (AdipoR1=0.64±0.03; 
AdipoR2=0.29±0.02; P>0.1 versus vehicle-treated group). 
AdipoR1-knockdown (KD) slightly increased TNFα-
induced ICAM-1 expression (Figure 1C) and superoxide 
generation (Figures 2B; P>0.05) and significantly increased 
nitrotyrosine formation (2.01±0.24 versus 3.36±0.48 pmol/
mg protein; P<0.05). AdipoR2-KD did not significantly 
modify the TNFα-induced inflammatory reaction without 
adiponectin treatment (Figure 1D). Most importantly, in 
AdipoR1-KD HUVEC, the inhibitory effects of gAPN on 
ICAM-1 expression (Figure 1C), superoxide generation 
(Figure 2B), and nitrotyrosine formation (Figure 2D) were 
all markedly (>87%) inhibited. In contrast, in AdipoR2-KD 
HUVEC, the anti-inflammatory (Figure 1D), antioxidative 
(Figure 2C), and antinitrative effects (Figure 2F) of gAPN 
were largely retained. In a separate experiment, the influence 
of AdipoR1-KD and AdipoR2-KD on the anti-inflammatory 
effects of fAPN was determined. The fAPN did not inhibit 
TNFα-induced inflammation as potently as gAPN (10 μg/
mL fAPN achieved comparable inhibitory effect as 2 μg/mL 
gAPN and further increasing fAPN up to 20 μg/mL failed 
to achieve better inhibitory effect; Figure 1B). The anti-in-
flammatory effect of fAPN (ICAM-1 expression presented in 
Figure 1 and oxidative/nitrative stress presented in Figure 2) 
was blocked largely by AdipoR1-KD (>76% inhibition; 
P>0.05 versus TNFα with vehicle; Figure 1C) and blocked 
modestly by AdipoR2-KD (<31% inhibition; P<0.05 versus 
TNFα with vehicle; Figure 1D). These results demonstrate 
that AdipoR1 largely mediates the anti-inflammatory effect 
of adiponectin in HUVEC.
Activation of nCDase by gAPN Contributes to Its 
Anti-Inflammatory Action
A recent study demonstrates that adiponectin activates nC-
Dase, increasing its catalytic activity in several cell types, in-
cluding β-cells, human embryonic kidney 239 cells, and liver 
cells. This effect is blocked in AdipoR1 and AdipoR2 double 
knockout (KO) cells.15 In HUVEC cells, neither TNFα nor 
adiponectin (gAPN and fAPN) exhibited significant effect 
on nCDase expression (Figure 3A). The ceramidase activa-
tion by gAPN is abolished virtually in AdipoR1-KD cells 
and preserved in AdipoR2-KD cells, indicating that gAPN 
increases nCDase activity in an AdipoR1-dependent fash-
ion (Figures 3B). The ceramidase activity of fAPN is par-
tially lost in AdipoR1 and AdipoR2-KD cells, with modestly 
stronger inhibitory effect when AdipoR1 is genetically in-
hibited, a results constant with recent report in liver cells 
(Figure 3B).15 To determine the role of nCDase activation in 
adiponectin’s anti- inflammatory action, nCDase expression 
was inhibited genetically by siRNA (Figure 3A, left, last 
lane). As expected, adiponectin failed to increase nCDase 
activity significantly in nCDase-KD HUVEC (Figure 3A, 
right). Most importantly, KD of nCDase markedly, although 
not completely, blocked the inhibitory effect of gAPN on 
TNFα-induced ICAM-1 expression (Figure 3C).
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Role of AMPK in Adiponectin Activation of  
nCDase and Anti-Inflammatory Action
AMPK is a well-recognized downstream signaling molecule 
of adiponectin.32 To determine the relationship between AMPK 
and nCDase in relation to adiponectin’s anti- inflammatory 
action, AMPK expression was inhibited genetically by siR-
NA (Figure 4A). As summarized in Figure 4B, transfection 
with siRNA against AMPKα successfully blocked AMPK- 
mediated acetyl-CoA carboxylase phosphorylation after 
adiponectin treatment. However, AMPK-KD had no effect 
on gAPN- induced nCDase activation (Figure 4C). Finally, 
AMPK-KD partially blocked the effect of gAPN on TNFα-
induced ICAM-1 expression (Figure 4D). These results 
demonstrate that adiponectin activates nCDase in an AMPK-
independent manner, but its anti-inflammatory effect is par-
tially mediated by AMPK signaling.
Role of Cav1 in Adiponectin-Induced nCDase 
Activation and Anti-Inflammatory Action
We recently demonstrated that, by holding AdipoR1 and its 
downstream signaling molecules in close proximity, form-
ing a caveolae-located adiponectin signalsome, Cav3 (the 
primary caveolin isotype expressed in cardiomyocytes) plays 
an essential role in adiponectin’s cardioprotective actions 
post myocardial ischemia/reperfusion.33 To clarify whether 
Cav1 (the primary caveolin isotype expressed in endothelial 
cells)34,35 is required for adiponectin activation of nCDase and 
anti-inflammatory action in HUVEC, Cav1 expression was 
downregulated by siRNA (Figure 5A, left). As summarized 
in Figure 5, Cav1-KD not only blocked adiponectin activation 
of nCDase activity (Figure 5A, right) but also virtually abol-
ished the inhibitory effect of adiponectin on TNFα-induced 
ICAM-1 expression (Figure 5B). To obtain more evidence 
Figure 1. Effect of adiponectin receptor 1 (AdipoR1)/AdipoR2 knockdown on adiponectin (APN)’s anti–intercellular adhesion 
molecule-1 (ICAM-1) effect. Human umbilical vein endothelial cells (HUVECs) were transfected with scramble or small interfering RNA 
(siRNA) against AdipoR1/AdipoR2 to knockdown AdipoR expression (A). Forty-eight hours after transfection, cells were pretreated with 
vehicle, globular adiponectin (gAPN) or full-length adiponectin (fAPN) followed by tumor necrosis factor (TNF)α treatment. Effect of APN 
on TNFα-induced ICAM-1 expression (12 hours post-TNFα treatment) was determined in scramble (B), AdipoR1 siRNA (C), and AdipoR2 
siRNA (D) transfected cells. *P<0.05, **P<0.01 vs TNFα-treated animals without APN treatment.
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that adiponectin activates nCDase and inhibits inflammatory 
response in a Cav1-dependent manner, the effect of S1P and 
SEW2871 (a selective S1P receptor 1 agonist) on TNFα- 
induced ICAM-1 expression was compared in wild-type (WT) 
and Cav1-KD cells. As summarized in Figure 5C, treatment 
with either S1P or SEW2871 significantly inhibited TNFα-
induced  ICAM-1 expression, and their anti-inflammatory ac-
tion was not blocked by Cav1-KD. These results demonstrate 
that direct application of S1P, the end catalytic product of the 
CDase system, bypasses Cav1-dependent nCDase activation 
and remains effective in blocking TNFα-induced inflamma-
tory action. This result also supports the necessity of Cav1 
for certain (such as AdipoR1 and insulin receptor) but not all 
membrane receptor-mediated signaling.
Cav1 Interacts With AdipoR1 and nCDase, Forming 
a Signaling Complex
Results presented in Figures 3B and 5A demonstrated that 
adiponectin increases nCDase activity in an AdipoR1 and 
Cav1-dependent fashion. To determine whether the effect of 
adiponectin on cellular levels of ceramide and S1P is also 
AdipoR1/Cav1 dependent, additional experiment was per-
formed. As illustrated in Figure 6A and 6B, treatment with 
adiponectin significantly attenuated TNFα-induced ceramide 
accumulation and increased S1P level, particularly at cellu-
lar membrane. These effects were virtually abolished when 
either AdipoR1 or Cav1 expression was genetically inhib-
ited, but largely preserved when AdipoR2 expression was 
genetically inhibited.
Cav1 regulates transmembrane signaling largely via en-
gagement of protein–protein interaction, facilitated by the 
scaffold domain located within Cav1 and the caveolin bind-
ing motif located within its partner proteins.36 In a final at-
tempt to clarify how Cav1 enables gAPN-initiated nCDase 
activation, 2 series of experiments were performed. First, 
the interaction between Cav1 and AdipoR1 was determined 
by immunofluorescent microscopy and coimmunoprecipi-
tation. As illustrated in Figure 6C, colocalization of Cav1 
and AdipoR1 was clearly observed (top). Cav1-KD did not 
alter AdipoR1 membrane localization (Figure 6C, bottom). 
Cav1 and AdipoR1 were coimmunoprecipitated in HUVEC 
(Figure 6D) and rat aortic endothelial cells (Figure 6E). 
Treatment with adiponectin had no significant effect on this 
protein–protein interaction (Figure 6D and 6E). Moreover, 
re-expression of WT Cav1 in Cav1-KD cells restored Cav1/
AdipoR1 interaction (Figure 6D and 6E, right, first lane). 
However, re-expression in Cav1-KD cells of a mutated 
Cav1, in which 5 aromatic residues within the scaffolding 
domain responsible for Cav1 interaction with partner pro-
teins were converted to alanine,37 did not reestablish Cav1/
AdipoR1 interaction (Figure 6D and 6E, right, second lane). 
Moreover, Cav1/nCDase interaction was also observed in 
aortic segment from mice treated with vehicle or gAPN 
(Figure 6F). Finally, coimmunoprecipitation identified 
adiponectin /Cav1 interaction, indicating that adiponectin 
binds the proposed Cav1/AdipoR1 complex (Figure 6G, up-
per). These results support basal Cav1/AdipoR1 interaction, 
a protein–protein interaction requisite for adiponectin acti-
vation of nCDase.
In a separate experiment, potential Cav1/AdipoR2 interac-
tion was determined by coimmunoprecipitation. As illustrated 
in Figure 6G (lower), interaction between Cav1/AdipoR2 is 
Figure 2. Effect of adiponectin receptor 1 (AdipoR1)/AdipoR2 knockdown on adiponectin (APN)’s antioxidative and antinitrative 
effect. Cells were treated as described in Figure 1. Effect of APN on tumor necrosis factor (TNF)α–induced superoxide production and 
nitrotyrosine formation was determined in scramble (A and D), AdipoR1 (B and E), and AdipoR2 (C and F) transfected cells. *P<0.05, 
**P<0.01 vs TNFα-treated animals without APN treatment. fAPN indicates full-length adiponectin; and gAPN, globular adiponectin.
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weak. The precise mechanisms responsible for the preferential 
interaction between Cav1 and AdipoR1 over AdipoR2 remain 
unclear at the present time. One possible explanation is that 
AdipoR1 contains 2 caveolin binding motifs, of which one 
is located within its cytosolic region, whereas AdipoR2 con-
tains only 1 caveolin binding motif, which is located within 
the transmembrane domain.
In second series of experiments, the interaction between 
Cav1 and nCDase was determined. Under basal conditions 
(vehicle), nCDase colocalization of Cav1 and nCDase is not 
robustly apparent (Figure 7A), and coimmunoprecipitation 
of Cav1 and nCDase is weak (Figure 7A). However, gAPN 
treatment significantly increased Cav1/nCDase interaction, 
as evidenced by clear colocalization (Figure 7A) and strong 
Figure 3. Adiponectin receptor 1 (AdipoR1)-dependent neutral ceramidase (nCDase) activation mediates adiponectin (APN) 
anti-inflammatory action. A, Transfection of human umbilical vein endothelial cells reduced nCDase expression (left) and blocked 
nCDase activation by APN (right). B, Effect of AdipoR1 and AdipoR2 knockdown on APN-induced nCDase activation. C, Effect of 
nCDase knockdown on the inhibitory action of APN on tumor necrosis factor (TNF)α–induced intercellular adhesion molecule-1 (ICAM-1) 
expression. **P<0.01 vs Con (A and B). *P<0.05, **P<0.01 vs TNFα-treated animals without APN treatment (C). fAPN indicates full-length 
adiponectin; and gAPN, globular adiponectin.
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coimmunoprecipitation (Figure 7B and 7C). Although the 
weak basal Cav1/nCDase interaction is not affected by 
AdipoR1-KD, the adiponectin-stimulated enhancement of 
Cav1/nCDase interaction is inhibited in AdipoR1-KD cells, 
but not altered in AdipoR2-KD cells (Figure 7B). The in-
teraction pattern between Cav1/nCDase clearly differs from 
Cav1/AdipoR1. Specifically, strong Cav1/AdipoR1 interac-
tion is observed during basal conditions but is not regulated 
by adiponectin. In contrast, basal Cav1/nCDase interaction 
is weak and is markedly enhanced after adiponectin treat-
ment. These results suggest that AdipoR1–Cav1–nCDase 
forms a complex and their association is enhanced after 
adiponectin treatment. To obtain more evidence supporting 
this notion, AdipoR1/nCDase interaction in the presence 
and absence of adiponectin was determined. As illustrat-
ed in Figure 7D, weak AdipoR1/nCDase interaction was 
observed and treatment with adiponectin significantly en-
hanced interaction.
Inhibitory Effect of Adiponectin on Leukocyte 
Rolling and Adhesion Is AdipoR1 and Cav1 
Dependent
To validate in vitro finding in a pathologically relevant in 
vivo model, interaction of Cav1 and nCDase and effect of 
AdipoR1/AdipoR2 and Cav1-KO on adiponectin inhibition 
of TNFα-induced leukocyte rolling and adhesion was deter-
mined using intravital microscopy. As illustrated in Figure 6E, 
Cav1/nCDase interaction and its enhancement were observed 
in aortic tissues from animals treated with vehicle or gAPN. 
Consistent with our previous report,30 in vivo treatment of WT 
mice with gAPN significantly inhibited TNFα-induced leuko-
cyte rolling and adhesion (Figure 8). Cav1-KO only slightly 
Figure 4. Role of AMP-activated protein kinase (AMPK) in adiponectin (APN)-induced neutral ceramidase (nCDase) activation. 
Transfection of human umbilical vein endothelial cells with AMPKα small interfering RNA (siRNA) reduced AMPKα expression (A) 
and blocked globular adiponectin (gAPN)–induced acetyl-CoA carboxylase (ACC) phosphorylation (pACC; B). In contrast, APN-
induced nCDase activation was not affected (C) and APN’s anti–tumor necrosis factor (TNF)α (intercellular adhesion molecule-1 
[ICAM-1] expression, D) was only partially inhibited when AMPK expression was genetically inhibited. *P<0.05, **P<0.01 vs respective 
control (Con).
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Figure 5. Role of caveolin-1 (Cav1) in adiponectin (APN)-induced neutral ceramidase (nCDase) activation and anti-inflammatory 
action. Human umbilical vein endothelial cell Cav1 expression was genetically inhibited by Cav1 small interfering RNA (siRNA; A, left). 
Cav1 knockdown (KD) blocked APN-induced nCDase activation (A, right) and anti-inflammatory effects of APN (intercellular adhesion 
molecule-1 [ICAM-1] expression, B). However, Cav1-KD had no significant effect on anti-inflammatory effects of sphingosine-1-
phosphate (S1P) and a selective S1P receptor 1 agonist (SEW2871; C). **P<0.01 vs respective control (A) or vs tumor necrosis factor 
(TNF)α–treated animals without APN treatment (B and C). fAPN indicates full-length adiponectin; and gAPN, globular adiponectin.
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Figure 6. Effect of adiponectin receptor 1 (AdipoR1)/AdipoR2 or caveolin-1 (Cav1) knockdown (KD) on cellular levels of 
ceramide (A) and sphingosine-1-phosphate (S1P; B) after tumor necrosis factor (TNF)α treatment in the presence and absence 
of globular adiponectin (gAPN). Representative photos from ≥5 repeated experiments. C, Cav1/AdipoR1 colocalization determined 
by immunofluorescent staining. Representative photos from ≥5 repeated experiments. D, Cav1/AdipoR1 interaction determined by 
coimmunoprecipitation in human umbilical vein endothelial cells (HUVECs). Cav1 was immunoprecipitated with antibody against Cav1 
and samples were immunoblotted with antibody against AdipoR1 (upper). To immunoprecipitate AdipoR1, HUVECs were transfected 
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(P>0.05) increased leukocyte rolling and adhesion after TNFα 
treatment, likely because of the increased basal nitric oxide 
production in these animals. In AdipoR1-KO mice, greater 
leukocyte rolling and adhesion were observed after TNFα 
treatment (P<0.05 versus WT). Most importantly, the inhibi-
tory effect of adiponectin on TNFα-induced leukocyte rolling 
and adhesion observed in WT mice was markedly inhibited 
in AdipoR1-KO mice (Figure 8) and completely abolished 
in Cav1-KO mice (leukocyte rolling, 45±3.3 cells/100 μm 
with adiponectin treatment versus 48±3.8 cells/100 μm with 
vehicle, P>0.1; leukocyte adhesion, 6.4±0.4 cells/100 μm 
with adiponectin versus 6.6±0.5 cells/100 μm with vehicle, 
P>0.1). Moreover, opposite from those results observed in 
AdipoR1-KO mice, the inhibitory effect of adiponectin on 
TNFα-induced leukocyte rolling and adhesion was largely 
preserved in AdipoR2-KO mice (Figure 8). Leukocyte rolling 
was slightly decreased in AdipoR2-KO mice compared with 
AdipoR1-KO mice during basal conditions (before TNFα 
challenge), without statistically significant difference. This 
result is consistent with previous observations that no sig-
nificant phenotype manifests in adiponectin-KO mice, unless 
challenged by metabolic or inflammatory stress.
Discussion
We have made 3 novel observations in this study. First, we 
demonstrate that the anti-inflammatory (determined by 
ICAM-1 expression), antioxidative (determined by superox-
ide production), and antinitrative (determined by nitrotyrosine 
formation) actions of gAPN are largely mediated by AdipoR1. 
At least 3 possibilities potentially explaining the superior func-
tion of AdipoR1 over AdipoR2 in the vascular system exist. It 
has been demonstrated previously that AdipoR1 has greater 
A
CB D
Figure 7. Cellular distribution of 
neutral ceramidase (nCDase) 
without adiponectin (APN) 
treatment (A, top) and effect of 
APN treatment on caveolin-1 
(Cav1) and nCDase interaction 
in wild-type (WT), Cav1-KD, or 
AdipoR1-KD human umbilical 
vein endothelial cells (HUVECs; 
A, confocal microscopy; B, 
immunoprecipitation). Note that 
APN-enhanced Cav1/nCDase 
interaction is blocked by AdipoR1, 
but not AdipoR2 knockdown. 
Cav1/AdipoR1/nCDase complex 
formation determined by 
immunoprecipitation (C and 
D). Representative images 
from ≥5 repeated experiments/
experimental conditions. gAPN 
indicates globular adiponectin.
with Myc-tagged AdipoR1 expressing vector and immunoprecipitated with antibody against Myc. Samples were 
then immunoblotted with antibody against Cav1 (lower). E, Cav1/AdipoR1 interaction determined by coimmunoprecipitation in rat aortic 
endothelial cells (RAECs). Re-expression in Cav1-KD cells of a mutated Cav1 (MUT), in which 5 aromatic residues within the scaffolding 
domain responsible for Cav1 interaction with partner proteins were converted to alanine. F, Cav1/nCDase interaction determined by 
coimmunoprecipitation in aortic segment from mice treated with vehicle or gAPN. Representative blots from ≥5 repeated experiments. 
G, APN/Cav1 complex forming (upper) and lack of AdipoR2/Cav1 interaction determined by immunoprecipitation (lower). Representative 
blots from ≥5 repeated experiments. IB indicates immunoblotting; WT, wild-type.
Figure 6 (Continued).
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gAPN binding affinity than AdipoR2.38,39 However, our results 
indicating fAPN (which has comparable binding affinity to 
both AdipoR1 and AdipoR2) exhibits an anti- inflammatory ef-
fect with stronger dependency on AdipoR1 argues against this 
possibility. A more likely explanation concerns prevalence. 
As AdipoR1 is the dominant adiponectin receptor isotype ex-
pressed in vascular tissue,39 it stands to reason AdipoR1 would 
be chiefly responsible for the biological effects of adiponec-
tin within the vascular system. Another possibility involves 
isotype-specific intracellular signaling. It is well recognized 
that membrane receptors possessing multiple subtypes (such 
as TNFα and β-adrenergic receptors) initiate different or 
even opposite intracellular signaling through different sub-
type activation. It is thus possible that AdipoR1 and AdipoR2 
may activate different intracellular signaling pathways, with 
anti-inflammatory, antioxidative, and antinitrative signaling 
preferentially mediated by AdipoR1. Regardless of which 
possibility is true, the current study strongly suggests that al-
though interventions activating AdipoR2 may better regulate 
hepatic metabolism, molecules strongly activating AdipoR1 
(such as the globular domain of adiponectin) may have great-
er therapeutic efficacy reducing vascular injury, particularly 
Figure 8. Effect of adiponectin receptor 1 (AdipoR1)/AdipoR2 knockout (KO) on adiponectin (APN) inhibition of tumor necrosis 
factor (TNF)α-induced leukocyte rolling and adhesion. Wild-type (WT), AdipoR1-KO, and AdipoR2-KO mice were pretreated with 
vehicle or globular adiponectin and leukocyte rolling and adhesion were observed using intravital microscopy after TNFα injection. The 
inhibitory effect of APN on TNFα-induced leukocyte rolling (A) and adhesion (B) observed in WT mice was virtually abolished in AdipoR1 
but not in AdipoR2-KO mice. No significant difference was observed in mean arterial blood pressure (MABP) among different treatment 
group (C). **P<0.01 vs TNFα-treated animals without APN treatment; #P<0.05, ##P<0.01 vs WT with the same treatment.
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from inflammatory changes. This conclusion is further sup-
ported by our previous study demonstrating that increased 
cardiomyocyte adiponectin production and resultant cardiac 
protection as a result of rosiglitazone treatment are primarily 
mediated by AdipoR1 activation.40
Second, we demonstrate that gAPN activates HUVEC nC-
Dase in an AMPK-independent fashion and nCDase activation 
significantly contributes to adiponectin’s anti-inflammatory 
function. In recent years, the biological activities of adipo-
nectin have been investigated extensively. Four major func-
tions (including metabolism-regulatory, anti-inflammatory, 
vasculoprotective, and cardioprotective effects) have been 
identified.41 Among multiple intracellular molecules activated 
after adiponectin binding of its specific membrane receptors, 
AMPK is the molecule most intensively investigated and is 
generally accepted as the most important intracellular signal-
ing molecule mediating adiponectin biological functions.32 
However, accumulating evidence suggests that the degree of 
AMPK involvement in biological regulation of adiponectin is 
dependent on organ and disease.42 Specifically, pharmacologi-
cal inhibition of AMPK activity or genetic inhibition of AMPK 
expression virtually abolishes the central metabolic actions 
of adiponectin,43,44 indicating that AMPK plays an essential 
role in hepatic metabolic regulation of adiponectin. However, 
we13 and others45 have demonstrated recently that the anti- 
ischemic/cardioprotective effects of adiponectin are largely 
AMPK-independent and involve the cyclooxygenase-2 and 
nuclear factor κB–mediated signaling pathways. Moreover, a 
recent elegant study reported that adiponectin exerts antiapop-
totic and cellular protective actions in an AMPK-independent, 
nCDase-dependent manner.15 Our current study demonstrates 
that unlike adiponectin’s metabolic and antiapoptotic actions 
(largely AMPK-dependent or largely AMPK-independent), 
adiponectin’s anti-inflammatory function is mediated by 
both the traditional AMPK pathway and the newly identified 
AMPK-independent nCDase activation pathway.
Third, and most importantly, we provide the first direct evi-
dence that Cav1 plays an essential role in AdipoR1-mediated 
nCDase activation and the anti-inflammatory actions of adi-
ponectin. At least 2 possibilities exist that may explain the 
necessity of Cav1 in adiponectin vascular signaling. First, as 
suggested by a recent experimental study, AdipoR1 may exert 
nCDase activity and catalyze the ceramide reaction. Because 
many cofactors required for enzymatic reactions enrich in 
caveolae, Cav1 loss may destroy the local environment op-
timized for nCDase catalytic reactions. The second and more 
likely explanation is that binding of adiponectin to AdipoR1 
recruits nCDase to the Cav1/AdipoR1 complex, facilitating 
their activation. This possibility is supported by the following 
4 experimental evidences: (1) Cav1 colocalizes and coimmu-
noprecipitates with AdipoR1, suggesting that these 2 proteins 
interact with each other; (2) mutation of 5 aromatic residues 
within the scaffolding domain known to be responsible for 
Cav1 interaction with its partner proteins not only inhibited 
Cav1/AdipoR1 interaction, but also blocked adiponectin acti-
vation of nCDase; (3) Cav1 interacts with nCDase in a different 
fashion than AdipoR1. Whereas the Cav1/AdipoR1 interac-
tion seems static, the Cav1/nCDase interface is dynamically 
regulated in an AdipoR1-dependent fashion; and (4) treatment 
with adiponectin significantly brought Cav1/nCDase in closer 
proximity to each other. Combs et al46
 previously reported 
that mice overexpressing adiponectin displays elevated Cav1 
levels in adipocyte and that Cav1-KO significantly reduces 
plasma adiponectin levels.47 Collectively, currently available 
experimental evidence supports that Cav1 plays essential roles 
in adiponectin production as well as adiponectin transmem-
brane signaling.
Cav1 is an essential molecule in EC caveolae formation. 
The role of Cav1 in atherosclerosis development is extremely 
complex. Either pro- and antiatherosclerotic effects have been 
reported, depending on cell types and disease development 
stage investigated.36,48 Although the dark mechanisms of Cav1 
promoting atherosclerosis have been investigated extensively, 
the bright side mechanisms of Cav1 preventing atherosclero-
sis remain largely unknown. Our current experiments demon-
strated that Cav1 interacts with AdipoR1, facilitating nCDase 
recruitment/activation on adiponectin binding, enabling the 
anti-inflammatory signaling of adiponectin.
Two limitations exist in the current study. First, we have 
provided clear evidence that adiponectin activation of 
AdipoR1 increases nCDase interaction with Cav1. However, 
how activation of AdipoR1 by adiponectin increases Cav1/
nCDase interaction remains unclear. Because AdipoR1 di-
rectly interacts with Cav1, it is possible that adiponectin bind-
ing to AdipoR1 may promote Cav1 conformational change 
as that caused by other Cav1 interacting molecule,49 thus in-
creasing its affinity with nCDase. This intriguing possibility 
will be deeply investigated in our future studies. Second, we 
have demonstrated that the anti-inflammatory/antioxidative/
antinitrative actions of adiponectin are largely mediated by 
AdipoR1, not AdipoR2. In addition to these 2 evolutionarily 
acquired specific receptors, other cell surface binding pro-
teins (such as T-cadherin) tether high molecular weight iso-
forms of adiponectin to the cell surface, possibly facilitating 
adiponectin/AdipoR interaction.50 The role of these proteins in 
adiponectin’s anti-inflammatory and vasculoprotective actions 
warrants future investigation.
In summary, we demonstrate for the first time that adipo-
nectin inhibits TNFα-induced inflammatory response via 
Cav1-mediated ceramidase recruitment and activation in an 
AdipoR1-dependent fashion. These experimental results not 
only deepen our understanding of adiponectin biological sig-
naling, but also suggest interventions facilitating AdipoR1/
Cav1/nCDase signaling (such as upregulating AdipoR1 ex-
pression and stimulating nCDase) may be novel vasculopro-
tective targets in the patient with diabetes mellitus.
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What Is Known?
•	 Type 2 diabetes mellitus affects >20 million people in the United States 
and is a major risk factor for cardiovascular diseases.
•	 Adiponectin (APN), produced by adipocytes, protects against cardio-
vascular injury from inflammation, through interaction with one or both 
of its receptor proteins (AdipoR1 or AdipoR2).
•	 Adiponectin has been shown to decrease inflammation by activating 
ceramidase. It is, however, unknown whether adiponectin protects 
against vascular injury from inflammation by activating ceramidase or 
if AdipoR1/AdipoR2 themselves function as ceramidases.
What New Information Does This Article Contribute?
•	 Adiponectin decreases inflammation primarily through AdipoR1.
•	 The activation of ceramidase significantly contributes to adiponectin’s 
anti-inflammatory function.
•	 The cell-signaling carrier protein caveolin-1 is essential for AdipoR1-
mediated ceramidase activation and the resultant anti-inflammatory 
actions of adiponectin.
Patients with both type 1 and type 2 diabetes mellitus experi-
enced more cardiovascular effects of inflammation than healthy 
individuals. Inflammation plays a major role in the cardiovascu-
lar complications of diabetes mellitus. Adiponectin is known to 
protect against cardiovascular injury caused by inflammation, 
through interaction with one or both of its receptor proteins 
(AdipoR1 and AdipoR2). It has been shown that adiponectin 
decreases inflammation through the enzyme ceramidase; how-
ever, it remains unknown whether adiponectin protects against 
vascular injury from inflammation by activating ceramidase or if 
AdipoR1/AdipoR2 themselves function as ceramidases. Here, we 
show that adiponectin decreases inflammation primarily through 
AdipoR1. Ceramidase activation significantly contributes to the 
anti-inflammatory effects of adiponectin. We demonstrate the ne-
cessity of caveolin 1 for AdipoR1-mediated ceramidase activation 
and the resultant anti-inflammatory actions of adiponectin. Our 
work contributes to a better understanding of adiponectin biologi-
cal signaling. Furthermore, these findings provide the framework 
for new approaches (such as increasing AdipoR1 protein expres-
sion or stimulation ceramidase activity) to decrease vascular in-
jury in patients with diabetes mellitus.
Novelty and Significance
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SUPPLEMENTAL METHODS 
Materials  
Human umbilical vein endothelial cells (HUVEC), rat aortic endothelial cells (RAEC) and cell 
culture reagents were purchased from Cell Applications (San Diego, CA). Fetal bovine serum 
was from Hyclone (Logan, CT). Antibody against caveolin-1 (Cav1), Pan-cadherin and Cy5-
conjugated secondary antibody were from Abcam. Antibodies against ICAM-1, ACC, 
phosphorylated ACC, and FITC, tetramethyl rhodamine (TRITC)-conjugated or horseradish 
peroxidase-conjugated secondary antibodies were from Cell Signaling Technology (Danvers, 
MA). Antibodies against AdipoR1 and AdipoR2 were from Bioss Inc (Woburn, MA). 
Antibodies against Ceramide and S1P were from Sigma (Saint Louis, MO) and Novus 
Biologicals (Littleton, CO). Recombinant human TNF-α protein (rhTNFα) and nCDase antibody 
were from R&D System (Minneapolis, MN). Recombinant human globular and full length APN 
(gAPN and fAPN) were from Peprotech, Inc (Rocky Hill, NJ). S1P and SEW2871 (a selective 
S1P receptor-1 agonist21) were from Cayman Chemical (Ann Arbor, MI). S1P was dissolved in 
70% ethanol. A stock solution for S1P was then made in 1% fatty acid–free bovine serum (FBS) 
albumin in PBS (137 mmol/L sodium chloride, 1.5 mmol/L potassium phosphate, 7.2 mmol/L 
sodium phosphate, 2.7 mmol/L potassium chloride, pH 7.4). An appropriate amount of the stock 
solution was then added to the cultured cells to yield the desired final concentration of S1P.  
 
Cell Culture and Treatments 
HUVEC (Passage 2-3) were plated on six-well plates and cultured in endothelial growth medium 
containing 10% fatal bovine serum, 2mM glutamine, 100U/ml penicillin, and 100 μg/ml 
streptomycin at 37°C and 5% CO2. Upon 80% confluence, cells were treated with vehicle, gAPN 
(2 µg/ml14) or fAPN (10 µg/ml). One hour after APN treatment, 10 ng/ml rhTNFα22 was added. 
Cells were collected 12 hours after TNFα treatment and oxidative/nitrative stress and ICAM-1 
expression were determined as described in detail below.  
 
Small Interfering RNA Transfection, Plasmid Construction, and Transfection 
siRNA duplexes against Cav-123, AdipoR124, AdipoR224, AMPKα124, and nCDase25 were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Universal control oligonucleotides 
(AllStars) from Santa Cruz served as negative control. HUVECs (80% confluent) were 
transfected via siIMPORTER siRNA transfection kit (Qiagen Science Inc. Benelux) per 
manufacturer’s protocol (final siRNA concentration: 50 nM).  The cells were then incubated at 
37°C with mixture of transfection regent and siRNA. After 5 hours, the cells in each well were 
replaced with fresh growth medium. At 72 hours after transfection, the cells transfected with 
control and experimental siRNA were used for experiments, harvested separately for extraction 
of total protein, and used for Western blot analysis or Immunoprecitipation assay. For plasmid 
construction, the cDNA encoding full-length (FL) human Cav-1 and muCav-1 were subcloned 
into pcDNA3.1 at Hind III and XbaI sites. The FL constructs then served as templates to further 
generate scaffolding domain alanine mutants (muCav-1) using standard PCR-based strategies. 
Scaffolding domain alanine region: DGIWKASFTTFTVTKYWFYR; Alanine mutagenesis 
region:DGIWKASATTAAVTKYAAYR. Endothelial cells were maintained in culture with 10% 
fetal bovine serum DMEM medium (Cell Applications, CA). For most experiments, cells in a 
60-mm culture plate were transfected with 2μg of plasmid DNA encoding muCav-1, FLCav-1, 
using LipofectAMINE (Qiagen) according to the manufacturer’s protocols. When cells were co-
transfected with plasmid DNA, empty vector (no cDNA insert) was used as control. 
Approximately 4 hours after transfection, culture medium was switched to 10% DMEM culture 
medium and incubation proceeded for 48 hours prior to the experiments. Then the cells will be 
harvested for extraction of total protein and used for the following experiments. 
  
Ceramidase Enzyme Activity Assay 
The nCDase enzyme activity was determined as previously reported, with minor modification26. 
Briefly, at experiment conclusion, cells were collected and washed twice with PBS. Cell pellets 
were resuspended in 100 μl 0.25 M sucrose solution, sonicated, and centrifuged at 15,000 g for 3 
minutes. The supernatant was collected and protein concentration was determined. A 25 μl 
sample containing identical protein amount, 75μl 25 mM phosphate buffer (pH 7.4), and 0.5 μl 4 
mM Rbm14-12 substrate solution in ethanol (final substrate concentration 40 μM; final ethanol 
concentration 1%) were loaded into each well of a 96-well plate. The same incubation mixture 
without supernatant served as negative control. The plate was incubated at 37°C for 1 hour 
without agitation. The enzymatic reaction was stopped by adding 25 μl methanol and 100 μl 
NaIO4 (2.5 mg/ml) in 200 mM glycine/NaOH buffer (pH 10.6) to each well. The plate was 
placed in a dark room for 1 hour. Fluorescent intensity was quantified via SpectraMax 
Microplate Reader (Molecular Devices, λex 355 nm, λem 446 nm).  
 
Determination of Superoxide and Peroxynitrite Content 
 Superoxide content was quantified by lucigenin enhanced luminescence, and the cellular origin 
of reactive oxygen species was determined by dihydroethidium staining (DHE, Molecular Probes, 
Carlsbad, CA). Briefly, histological detection of superoxide anion in situ was performed using 
fresh-cultured endothelial cells stained with DHE (5µmol/L) in medium for 5 minutes at 37°C. 
The intensity of the fluorescence signal was analyzed using IPlab Imaging Software 4.5 
(BioVision, Rockingham, VT). Nitrotyrosine content, the footprint of peroxynitrite formation, 
was quantified by a modified ELISA procedure. In brief, endothelial cells were homogenized in 
ice cold PBS (1:10 w/v) using sonication with a dismembrator (Fisher Scientific, Pittsburgh, PA). 
The homogenates were centrifuged for 10 min at 12,000g at 4°C. The supernatants were 
collected and protein concentrations were determined by Bio-Rad method. A nitrated protein 
solution was prepared for use as a standard by adding 8 μl of chemically synthesized ONOO− 
(concentration: 100-120 mM) to 3 ml of 0.04% (0.4 mg/ml) BSA in PBS. The amount of 
nitrotyrosine present in the peroxynitrite-treated BSA solution was measured at 430 nm using a 
spectrophotometer (Beckman DU 640, Fullerton, CA) and expressed as nanograms per milliliter. 
The stock solution of the peroxynitrite-treated BSA was diluted with PBS (final nitrotyrosine 
concentration, 0.75–75 ng/ml). These standard samples, along with samples from endothelial 
cells (protein concentration, 4 mg/ml) were applied to disposable sterile ELISA plates (Corning 
Glassworks, Corning, NY) and allowed to bind for 1 h at 37°C in a microincubator shaker 
(Teitec Co., San Jose, CA). After blocking nonspecific binding sites with 1% BSA in PBS, the 
wells were incubated for 60 min at 37°C with a rabbit polyclonal anti-nitrotyrosine primary 
antibody (Millipore) and subsequently for 60 min at 37°C with a peroxidase-conjugated goat 
anti-rabbit IgG secondary antibody (1:1000, Amersham Pharmacia Biotech, Inc. Piscataway, NJ). 
After washing the plates, the peroxidase reaction product was generated usingO-
phenylenediamine dihydrochloride (2.2 mM) (Abbott Diagnostics, Abbott Park, IL). The plate 
was incubated for 20 min in the dark at room temperature, and the reaction was stopped by 
addition of 20 ml of 2 M H2SO4. The optical density was measured at 460 nm with a SpectraMax 
L microplate reader (MD LLC, Sunnyvale, CA). The amount of nitrotyrosine content in samples 
was calculated using standard curves generated from nitrated BSA containing known amounts of 
nitrotyrosine. 
 
Confocal Immunofluorescence Microscopy 
30 minutes after vehicle or gAPN treatment, HUVEC were fixed with 4% 
paraformaldehyde/PBS in µ-Slide (ibidi LLC, Verona, WI) for 15 minutes followed by PBS 
washing. Cells were first treated with antibodies against AdipoR1, Cav1, or nCDase (at 1:200), 
followed by incubation with tetramethyl rhodamine (TRITC)-conjugated anti-rabbit IgG and 
Cy5-conjugated anti-goat IgG (1:200). For Ceramide and S1P staining, cells were fixed with 4% 
paraformaldehyde/PBA for 2 min. Cells were then washed with ddH2O (2 min) and TBS (pH7.6, 
5 min). Nonspecific binding sites were blocked by 2x casein solution (Vector Inc.) for 10 min at 
room temperature. The primary antibodies were prepared with TBS solution containing 5µM of 
CaCl2 and cells were incubated with antibody for 2 h at room temperature. After 10 min washing 
with TBS under agitation, cells were incubated with florescence labeled secondary antibody.  
After washing with PBS, coverslips were mounted utilizing an anti-fade solution (KPL, 
Gaithersburg, MD). Samples omitting the primary antibody served as negative control. Slides 
were visualized by a FV1000 confocal microscope with x60 oil-immersion objective lenses 
(Olympus, Tokyo, Japan). Fluorescent images were obtained by a digital camera and analyzed 
with Fluoview software (Olympus). 
 
Immunoblotting and Co-Immunoprecipitation 
HUVECs or RAECs were lysed with cold lysis buffer [50 mM Tris-HCl, pH 7.4/100 mM 
NaCl/0.1 mM EGTA/0.1 mM EDTA/1% Triton X-100/1 mM sodium orthovanadate/20 mM 
NaF/1 mM Na4P2O7 and cocktail protease inhibitor; For Cav-1 immnoprecipitation, 10mM Tris, 
pH 8.0/60 mM n-octyl β-D-glucopyranoside/150 mM NaCl/1 mM sodium orthovanadate/20 mM 
NaF/1 mM Na4P2O7 and cocktail protease inhibitor]29, 30. After homogenization and 
centrifugation, the supernatant was collected. For immunoblotting, proteins were separated on 
SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were then incubated 
with primary antibodies (anti-ICAM-1, anti-nCDase, anti-ACC, anti-pACC, anti-AdipoR1, anti-
Cav1, and anti-GAPDH) and HRP-conjugated secondary antibody. The blot was developed with 
a Supersignal Chemiluminescence detection kit (Pierce, Rockford, IL). Bands were visualized by 
a Kodak Image Station 4000R Pro (Rochester, NY). For co-immunoprecipitation, cell lysates 
were pre-cleared with corresponding nonimmune IgG, and incubated together with protein A 
plus-Sepharose for 30 minutes at 4°C. Cleaned lysates were then incubated with 2 µg of either 
anti-Cav1 or anti-nCDase antibodies. Cell lysates were then incubated with protein A plus-
Sepharose overnight at 4°C. Nonimmune rabbit IgG served as negative control. Protein A beads 
were then extensively washed with lysis buffer. Proteins were eluted from beads, and resolved by 
elusion buffer. Samples with 2XSDS sample buffer were heated and separated by electrophoresis. 
After transfer to PVDF membranes, proteins were immunoblotted with anti-AdipoR1 (for 
Cav1/AdipoR1 interaction) or anti-Cav1 (for Cav1/ceramidase interaction) as described above.  
Intravital Microscopy Analysis of Leukocyte Rolling and Adhesion 
Leukocyte rolling and adhesion was assayed in mesenteric post-capillary venules by intravital 
microscopy as we previously described31. In brief, mice were pretreated with gAPN (first dose: 
1.0 µg/g, i.p., 24 hours before TNFα administration; second dose: 1 µg/g, i.p.). 30 min after the 
second dose of APN, mice were treated with recombinant TNFα (1.0 µg/kg, i.p) for 2 hours. 
Following exteriorization of a loop of ileum tissue via a midline laparotomy, the ileum was 
placed in a temperature-controlled fluid-filled Plexiglas chamber and trans-illuminated for 
bright-field observation of the peri-intestinal microcirculation. The ileum and mesentery were 
perfused throughout the experiment with a buffered K-H solution (pH 7.4, 37°C). Three to four 
straight, unbranched segments of post-capillary venules with lengths of >100 μm and diameters 
between 25 and 40 μm were studied in each mouse using an Eclipse FN1 Microscope (Nikon 
Corp), and the image recorded and analyzed on A WIN XP Imaging Workstation. Leukocyte 
rolling was defined as the number of leukocytes rolling past a fixed point per minute; leukocyte 
adherence was defined as the number of leukocytes firmly adhered to 100-μm length of 
endothelium for at least 30 seconds. Rolling and adhesion were quantitated 4 hours following 
TNF-α injection. Venular blood velocity (V) was measured using the Microvessel Velocity OD-
RT optical Doppler velocimeter (Circusoft Instrumentation) with corresponding software. 
Venular wall shear rate (γ) was calculated using the formula: γ=4.9×8(Vmean /D), where D is 
the venule diameter. 
 
 
 
 
 
